वैकल्पिक एवं एकीकृत चिकित्सा

Evaluation of Distribution and Frequency of Neuroblastoma in Children in Azzahra Hospital of Isfahan between 1996-2007 and 2 Years Survival

Abstract

Davood Ershadi*, Mahmood Ashrafi, Mehrdad Memarzade and Ziba Farajzadegan

Neuroblastoma is more frequent extra cranial childhood malignancy the goal of this study is evaluate pattern of neuroblastoma and 2 years survival in isfahan and comparison with others studies. The counted cases were 45 patients.25 of them were male (55.6%) and 20 of them were female (44.4%). Female/male ratio was 1.25. Primary sites of tumor in 32 patients were retroperitoan (71%), in 8 patients were posterior mediastineum 17.8%, in 3 patients were cervical 6.7% in pelvis 4.4%. In clinical manifestation the abdominal mass is predominant (17 patients 37.8%), abdominal pain in 6 patients 13.3%, abdominal distention in 2 patients (4.4%) fever in 6 patients (13.3%), cervical mass in 4 patients (6.7%), weight loss in 1 patient (2.2%). In evaluation of bone marrow biopsy 22 patient have metastasis to bone (48.8%) and 23 patients have not metastasis (51.1%). In evaluation of peripheral blood smear 29 patient have hypochrome RBC (64.4%) 32 patients have anisocytosis (71.1%), 30 patients have microcytosis (66.7%), 7 patients have low platelets (15.6%), 6 patients have high platelets 13.3%, 5 patients have lymphocytosis (11.1%), 7 patients have atypical lymphocyte (15.6%) 35 cases of them had died (77.8%), and 10 patients had been being alive (22.2%). Statistical analysis show us mean survival of patient with surgical process was 38.8 months and for patient without surgery was 30.6 months. Total 30 month survival in our study was 50%. Female/male ratio (1.25) in our study is same as other studies like a study in Saudi Arabia 53% of our cases was under 20 months 0.44% of them between 20-80 months 3% over 10 years as same result of others study. Retroperitoan is dominant primary site (71%) like other studies. But there is not significant relation between metstatic bone marrow biopsy and survival. Our result about prognosis (30 month survival was 50%) is less than other countries.